Petrus Trust Company LTA Grows Position in GoodRx Holdings, Inc. $GDRX

Key Points

• Petrus Trust Company LTA increased its stake in GoodRx Holdings, Inc. by 7.4%, acquiring an additional 216,926 shares, and now holds 3,167,015 shares, making GoodRx 19th in its portfolio.
• GoodRx's share price recently fell 6.5%, with current valuations at $4.00, down from a 12-month high of $8.06.
• Consensus ratings among analysts for GoodRx range from "Buy" to "Hold," with a current price target of $5.80 following recent downgrades from several firms.

Petrus Trust Company LTA grew its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 7.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,167,015 shares of the company's stock after buying an additional 216,926 shares during the quarter. GoodRx makes up 1.3% of Petrus Trust Company LTA's portfolio, making the stock its 19th biggest holding. Petrus Trust Company LTA owned 0.83% of GoodRx worth $13,967,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in GDRX. Citizens Financial Group Inc. RI bought a new position in shares of GoodRx in the first quarter worth about $44,000. Jump Financial LLC bought a new position in shares of GoodRx in the first quarter worth about $49,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of GoodRx by 20,956.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 14,529 shares of the company's stock worth $64,000 after buying an additional 14,460 shares during the period. Headlands Technologies LLC raised its stake in shares of GoodRx by 213.2% in the first quarter. Headlands Technologies LLC now owns 14,830 shares of the company's stock worth $65,000 after buying an additional 10,095 shares during the period. Finally, Total Wealth Planning & Management Inc. bought a new position in shares of GoodRx in the fourth quarter worth about $68,000. Institutional investors own 63.77% of the company's stock.

Analyst Ratings Changes

GDRX has been the topic of several recent research reports. UBS Group decreased their price objective on GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Raymond James Financial downgraded GoodRx from a "strong-buy" rating to an "outperform" rating in a research note on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a $6.00 price objective on shares of GoodRx in a research note on Monday, August 11th. Five research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat, GoodRx has a consensus rating of "Hold" and an average price target of $5.80.

GoodRx Price Performance

Shares of NASDAQ:GDRX traded up $0.12 during trading on Monday, hitting $4.12. 3,456,462 shares of the company's stock were exchanged, compared to its average volume of 5,878,624. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21. GoodRx Holdings, Inc. has a 52-week low of $3.31 and a 52-week high of $7.90. The business's 50-day simple moving average is $4.49 and its 200 day simple moving average is $4.45. The company has a market cap of $1.43 billion, a price-to-earnings ratio of 41.20, a PEG ratio of 1.74 and a beta of 1.23.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The business had revenue of $203.07 million for the quarter, compared to analysts' expectations of $205.72 million. During the same quarter in the prior year, the business posted $0.08 EPS. The business's revenue for the quarter was up 1.2% compared to the same quarter last year. As a group, equities analysts predict that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Insiders Place Their Bets

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of the firm's stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $4.05, for a total transaction of $64,864.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 4.17% of the stock is owned by corporate insiders.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.